Contact this trialFirst, we need to learn more about you.
Inhibitor
Pemigatinib for Bladder Cancer
Recruiting2 awardsPhase 2
Washington, District of Columbia
This trial is testing a drug called Pemigatinib to see if it can treat patients with a history of low- or intermediate-risk non-muscle invasive bladder cancer who have recurrent tumors. If the drug is effective, it will be given to patients 4-6 weeks before they undergo a standard treatment called transurethral resection of bladder tumor.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.